ArticleNPJ precision oncology2018
Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways.
Open access · goldAbstract read
In one paragraph
Article in NPJ precision oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 45 citations in OpenAlex.
- Article
- Multi-omics characterization of IDH-mutant astrocytoma-derived cell lines reveals NOTCH-regulated plastic quiescent astrocyte-like state and insights into progression.Acta neuropathologica communications · 2026Article
- Murine modeling of IDH-mutant 1p/19q-codeleted oligodendroglioma reveals genotype specific phenotypes.bioRxiv : the preprint server for biology · 2026Article
- Prognostic Impact of Calcification, Corpus Callosum Invasion, and CDKN2A/B Hemizygous Deletion in Oligodendroglioma: A Single-center Retrospective Study.Neurologia medico-chirurgica · 2026Article
- Targeting NOTCH-immune crosstalk in gliomas: from mechanisms to therapeutics.Frontiers in oncology · 2026Review
- Advances in the management of patients with IDH-mutant glioma.The oncologist · 2025Review
- Genomic landscape of diffuse glioma revealed by whole genome sequencing.Nature communications · 2025Article
- IDH mutant high-grade gliomas.Frontiers in molecular neuroscience · 2025Review
- The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?Neuro-oncology · 2024Review
- HOXD12 defines an age-related aggressive subtype of oligodendroglioma.Acta neuropathologica · 2024Article
- The 2021 World Health Organization Central Nervous System Tumor Classification: The Spectrum of Diffuse Gliomas.Biomedicines · 2024Review
- Notch signaling pathway in cancer: from mechanistic insights to targeted therapies.Signal transduction and targeted therapy · 2024Review
- Review
- Long-term follow up of patients with WHO grade 2 oligodendroglioma.Journal of neuro-oncology · 2023Article
- Genetic Inactivation ofCancers · 2022Article
- PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications.Neuro-oncology · 2022Article
- Characteristics of Anaplastic Oligodendrogliomas Short-Term Survivors: A POLA Network Study.The oncologist · 2022Article
- Challenges of imaging interpretation to predict oligodendroglioma grade: a report from the Neuro-Oncology Branch.CNS oncology · 2022Article
- Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System.Laboratory investigation; a journal of technical methods and pathology · 2022Review
- A Composite Bioinformatic Analysis to Explore Endoplasmic Reticulum Stress-Related Prognostic Marker and Potential Pathogenic Mechanisms in Glioma by Integrating Multiomics Data.Journal of oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 6 institutions in 2 countries.
Sameer H Halani1Emory University School of Medicine, Atlanta, GA USA.
Safoora Yousefi2Department of Biomedical Informatics, Emory University, Atlanta, GA USA.
Jose Velazquez Vega3Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA USA.
Michael R Rossi3Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA USA.
Zheng Zhao4Department of Neurosurgery, Tiantan Hospital, Capital Medical University, Beijing, China.
Fatemeh Amrollahi2Department of Biomedical Informatics, Emory University, Atlanta, GA USA.
Chad A Holder5Department of Radiology, Emory University, Atlanta, GA USA.
Amelia Baxter-Stoltzfus1Emory University School of Medicine, Atlanta, GA USA.
Jennifer Eschbacher6Department of Neuropathology, Barrow Neurological Institute, Phoenix, AZ USA.
Brent Griffith7Department of Radiology, Henry Ford Health System, Detroit, MI USA.
Jeffrey J Olson1Emory University School of Medicine, Atlanta, GA USA.
Tao Jiang4Department of Neurosurgery, Tiantan Hospital, Capital Medical University, Beijing, China.
Joseph R Yates11Divisions of Pathology, Ophthalmology, and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD USA.
Charles G Eberhart11Divisions of Pathology, Ophthalmology, and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD USA.
Laila M Poisson8Josephine Ford Cancer Institute, Henry Ford Health System, Detroit, MI USA.
Lee A D Cooper *1Emory University School of Medicine, Atlanta, GA USA.
Daniel J Brat *14Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL USA.
Emory University · USCapital Medical University · CNHenry Ford Health System · USJohns Hopkins University · USBarrow Neurological Institute · USNorthwestern University · US
Funding
Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
$92.1MWinship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5MAtlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8MAdvanced Development of an Open-source Platform for Web-based Integrative Digital Image Analysis in CancerU24CA194362 · NCI · EMORY UNIVERSITY · PI COOPER, LEE, GUTMAN, DAVID ANDREW · 2015 to 2019
$3.6MMolecular Target Variation Across Environments and at Margins of GlioblastomaR01CA176659 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BRAT, DANIEL J, HADJIPANAYIS, CONSTANTINOS GEORGE · 2013 to 2017
$2.3MAtlanta Clinical and Translational Science Institute (ACTSI) RenewalTL1TR000456 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$1.2MMultiscale Framework for Molecular Heterogeneity AnalysisK22LM011576 · NLM · EMORY UNIVERSITY · PI COOPER, LEE · 2013 to 2015
$485kNCATS NIH HHS TL1 TR000456NCATS NIH HHS UL1 TR000454NCATS NIH HHS UL1 TR002378NCI NIH HHS P30 CA138292NCI NIH HHS R01 CA176659NCI NIH HHS U24 CA194362NLM NIH HHS K22 LM011576
Abstract
Oligodendrogliomas are diffusely infiltrative gliomas defined by
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.